NCT02713763View on ClinicalTrials.gov

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions
Pancreatic Neuroendocrine Tumour Metastatic
Interventions
DRUG

Sunitinib

Sunitinib 37.5 mg/day

Trial Locations (9)

14004

Hospital Reina Sofía, Córdoba

20014

Hospital Universitario Donostia, Donostia / San Sebastian

28034

Hospital Ramón y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

30008

Hospital General Universitario J.M. Morales Meseguer, Murcia

33011

Hospital Universitario Central de Asturias, Oviedo

41013

Complejo Hospitalario Regional Virgen Del Rocío, Seville

46009

Instituto Valenciano de Oncología, Valencia

08035

Hospital Universitario Valle de Hebrón, Barcelona

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Grupo Espanol de Tumores Neuroendocrinos

OTHER

NCT02713763 - Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib | Biotech Hunter | Biotech Hunter